1. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977;49:511–533.
2. Buckner CD, Epstein RB, Rudolph RH, Clift RA, Storb R, Thomas ED. Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. Blood 1970;35:741–750.
3. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975;292:895–902.
4. Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008;112:3574–3581.
5. Cutler C, Ballen KK. Improving outcomes in umbilical cord blood transplantation: state of the art. Blood Rev 2012;26:241–246.
6. Arcese W, Mangione I, Picardi A. Algorithm for donor selection in 2011. Curr Opin Hematol 2011;18:401–407.
8. Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 2012;119:1972–1980.
9. Lown RN, Shaw BE. Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision. Bone Marrow Transplant 2013;48:210–21.
10. Shim JS, Cho B, Kim M, et al. Early apoptosis in CD34+cells as a potential heterogeneity in quality of cryopreserved umbilical cord blood. Br J Haematol 2006;135:210–213.
12. Petersdorf EW, Malkki M. Human leukocyte antigen matching in unrelated donor hematopoietic cell transplantation. Semin Hematol 2005;42:76–84.
13. Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 2007;110:2235–2241.
14. Kanda Y, Kanda J, Atsuta Y, et al. Impact of a single human leucocyte antigen (HLA) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods: a retrospective analysis of 3003 patients from the HLA Working Group of the Japan Society for Blood and Marrow Transplantation. Br J Haematol 2013;161:566–577.
15. Cho BS, Yoon JH, Shin SH, et al. Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia. Biol Blood Marrow Transplant 2012;18:1552–1563.
16. Kanda J, Ichinohe T, Kato S, et al. Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction. Leukemia 2013;27:286–294.
17. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLAmismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006;107:3065–3073.
18. Lee KH, Lee JH, Lee JH, et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood 2011;118:2609–2617.
19. Akatsuka Y, Warren EH, Gooley TA, et al. Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol 2003;123:671–675.
21. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339:1186–1193.
22. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997;89:3864–3872.
23. Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 1995;60:778–783.
24. Tiercy JM, Villard J, Roosnek E. Selection of unrelated bone marrow donors by serology, molecular typing and cellular assays. Transpl Immunol 2002;10:215–221.
25. Begovich AB, McClure GR, Suraj VC, et al. Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. J Immunol 1992;148:249–258.
26. Petersdorf EW, Longton GM, Anasetti C, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997;89:1818–1823.
27. Anasetti C, Hansen JA. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfus Sci 1994;15:221–230.
28. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923–1930.
29. Ho VT, Ki HT, Liney D, et al. HLA-C mismatch is associated with inferior survival after unrelated donor non myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 2006;37:845–850.
30. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998;92:3515–3520.
31. Kim HJ, Min WS, Eom KS, et al. Hematopoietic stem cell transplantation with using multinational unrelated donors for acute myelogenous leukemia. Korean J Hematol 2007;42:98–105.
32. Kim HJ, Min WS, Cho BS, et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009;15:704–717.
33. Petersdorf EW, Gooley T, Malkki M, et al. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. Br J Haematol 2001;112:988–994.
34. Varney MD, Lester S, McCluskey J, Gao X, Tait BD. Matching for HLA DPA1 and DPB1 alleles in unrelated bone marrow transplantation. Hum Immunol 1999;60:532–538.
35. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching ofclass I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor: Japan Marrow Donor Program. N Engl J Med 1998;339:1177–1185.
36. Morishima Y, Yabe T, Matsuo K, et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007;13:315–328.
37. McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000;95:2219–2225.
38. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003;102:814–819.
39. Kim HJ. HLA mismatched allogeneic hematopoietic stem cell transplantation. Korean J Hematol 2007;42:1–14.
40. Kim HJ, Choi Y, Jeong HY, Min WS, Kim CC, Kim TG. Killer cell immunoglobulin-like receptor (KIR) analysis in adult Korean patients with acute myeloid leukemia. Korean J Hematol 2006;41:139–148.
41. Norman PJ, Stephens HA, Verity DH, Chandanayingyong D, Vaughan RW. Distribution of natural killer cell immunoglobulin-like receptor sequences in three ethnic groups. Immunogenetics 2001;52:195–205.
42. Crum KA, Logue SE, Curran MD, Middleton D. Development of a PCR-SSOP approach capable of defining the natural killer cell inhibitory receptor (KIR) gene sequence repertoires. Tissue Antigens 2000;56:313–326.
43. Niokou D, Spyropoulou-Vlachou M, Darlamitsou A, Stavropoulos-Giokas C. Distribution of killer cell immunoglobulin-like receptors in the Greek population. Hum Immunol 2003;64:1167–1176.
44. Yin XL, Guo KY, Ma HJ, et al. Killer immunoglobulin-like receptor gene distribution in Guangdong Han population. Di Yi Jun Yi Da Xue Xue Bao 2004;24:1416–1418.
46. Kim HJ, Choi Y, Min WS, et al. The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia. Transplantation 2007;84:1082–1091.
47. Kim SY, Choi HB, Yoon HY, et al. Influence of killer cell immunoglobulin-like receptor genotypes on acute graft-vshost disease after unrelated hematopoietic stem cell transplantation in Koreans. Tissue Antigens 2007;69(Suppl 1):114–117.
48. Kim HJ, Min WS, Kim YJ, Kim DW, Lee JW, Kim CC. Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution. Bone Marrow Transplant 2005;35:959–964.
50. Goker H, Ozdemir E, Uz B, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience. Transfus Apher Sci 2013;49:590–599.
51. Im HJ, Koh KN, Choi ES, et al. Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transplant 2013;19:754–759.
52. Koh KN, Im HJ, Kim BE, et al. Haploidentical haematopoietic stem cell transplantation using CD3 or CD3/CD19 depletion and conditioning with fludarabine, cyclophosphamide and antithymocyte globulin for acquired severe aplastic anaemia. Br J Haematol 2012;157:139–142.
53. Rachamim N, Gan J, Segall H, et al. Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 1998;65:1386–1393.
54. Martelli MF, Reisner Y. Haploidentical 'megadose' CD34+ cell transplants for patients with acute leukemia. Leukemia 2002;16:404–405.
55. Franco A, Terenzi A, Tabilio A, et al. Full haplotypemismatched hematopoietic stem cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005;23:3447–3454.
56. Lee KH, Lee JH, Lee JH, et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Biol Blood Marrow Transplant 2009;15:61–72.
57. Kim HJ, Min WS, Choi SM, et al. Haplotype mismatch transplantation using high-dose CD34+ cells with stratified new conditioning regimens in patients with acute myeloid leukemia. Korean J Hematol 2003;38:221–227.
58. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002;100:1935–1947.
59. Zhao XY, Chang YJ, Huang XJ. Conflicting impact of alloreactive NK cells on transplantation outcomes after haploidentical transplantation: do the reconstitution kinetics of natural killer cells create these differences? Biol Blood Marrow Transplant 2011;17:1436–1442.
60. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097–2100.
61. Wang Y, Liu DH, Liu KY, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013;119:978–985.
62. Cho BS, Choi HB, Kim HJ, Min WS, Kim CC, Kim TG. Typing by nested PCR-SSP approach raises a question about the feasibility of using this technique for detecting fetomaternal microchimerism. Leukemia 2006;20:896–898.
63. Lee JY, Park S, Kim DC, Shin SH, Min WS, Kim HJ. A VEGFR-3 antagonist increases IFN-gamma expression on low functioning NK cells in acute myeloid leukemia. J Clin Immunol 2013;33:826–837.